Aptinyx Cashes In Post-Naurex Cache With $65m Series A

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.

Evanston, Illinois-based Aptinyx will use its Series A cash to begin a Phase I clinical trial for its first drug...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip